ABSTRACT
The aim of this chapter is to explore positive parenting during COVID-19 times in Spain. The study was not only interested whether positive parenting occurred during the health crisis, but also which predictors explain the process. For doing this, this study is based on 583 Spanish parents. The study was conducted during the State of Alarm in Spain (March-May 2020), where the country experienced a full lockdown. Our results showed that stress, family support, family belongingness, prayer and religious life, and family trust have a significant positive relationship with some of the four dimensions of positive parenting, (bonding, formative, protective and reflexive competences). This research enriches the extensive body of scholarship on positive parenting in at least three ways. First, it explores positive parenting under extraordinary circumstances (COVID-19). Second, it expands the research in Spain with very recent data. Finally, it contributes to understand better the antecedents of positive parenting among contemporary families. © 2023 selection and editorial matter, Maria Teresa Russo, Antonio Argandoña and Richard Peatfield;individual chapters, the contributors.
ABSTRACT
PURPOSE: To analyze the associations between cholecalciferol or calcifediol supplementation, serum 25-hydroxyvitamin D (25OHD) levels and COVID-19 outcomes in a large population. METHODS: All individuals ≥ 18 years old living in Barcelona-Central Catalonia (n = 4.6 million) supplemented with cholecalciferol or calcifediol from April 2019 to February 2020 were compared with propensity score-matched untreated controls. Outcome variables were SARS-CoV2 infection, severe COVID-19 and COVID-19 mortality occuring during the first wave of the pandemic. Demographical data, comorbidities, serum 25OHD levels and concomitant pharmacological treatments were collected as covariates. Associations between cholecalciferol or calcifediol use and outcome variables were analyzed using multivariate Cox proportional regression. RESULTS: Cholecalciferol supplementation (n = 108,343) was associated with slight protection from SARS-CoV2 infection (n = 4352 [4.0%] vs 9142/216,686 [4.2%] in controls; HR 0.95 [CI 95% 0.91-0.98], p = 0.004). Patients on cholecalciferol treatment achieving 25OHD levels ≥ 30 ng/ml had lower risk of SARS-CoV2 infection, lower risk of severe COVID-19 and lower COVID-19 mortality than unsupplemented 25OHD-deficient patients (56/9474 [0.6%] vs 96/7616 [1.3%]; HR 0.66 [CI 95% 0.46-0.93], p = 0.018). Calcifediol use (n = 134,703) was not associated with reduced risk of SARS-CoV2 infection or mortality in the whole cohort. However, patients on calcifediol treatment achieving serum 25OHD levels ≥ 30 ng/ml also had lower risk of SARS-CoV2 infection, lower risk of severe COVID-19, and lower COVID-19 mortality compared to 25OHD-deficient patients not receiving vitamin D supplements (88/16276 [0.5%] vs 96/7616 [1.3%]; HR 0.56 [CI 95% 0.42-0.76], p < 0.001). CONCLUSIONS: In this large, population-based study, we observed that patients supplemented with cholecalciferol or calcifediol achieving serum 25OHD levels ≥ 30 ng/ml were associated with better COVID-19 outcomes.